Press releases

System is the world's first rechargeable SCS device; approval provides physicians with an additional diagnostic option for patients with chronic intractable pain.

World's first rechargeable SCS device approved for peripheral nerve stimulation for patients with chronic intractable pain of the trunk.

Newly revised European Society of Cardiology guidelines include LAA closure devices.

PARIS (July 27, 2012) -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended June...

Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and...

Boston Scientific Corporation (NYSE: BSX) will webcast its second-quarter 2012 financial results conference call on Thursday, July 26, at 8:00 a.m....

Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug...

Boston Scientific Corporation (NYSE: BSX) welcomes final passage today by the United States Senate of "The Food and Drug Administration Safety and...

Natick, MA (June 14, 2012) –Warren Wang has been appointed Vice President and Managing Director of Boston Scientific Corporation’s (NYSE:BSX) operations in China. Mr. Wang is responsible for...

Next-generation wireless remote patient management system enabled for INGENIO™ family of pacemakers is now in use in Europe

Adds first and only commercially available subcutaneous ICD technology that offers new life-saving therapy option to patients at risk of sudden cardiac arrest.

Medical device tax would stifle innovation

Event to be webcast live and will include detailed review of Bronchial Thermoplasty opportunity.

PROMUS Element plus stent system offers physicians the broadest array of Everolimus drug-eluting stent lengths and diameters in the U.S.

Devices projected to have nearly twice the longevity of comparable products

Indication provides new therapeutic option for extraction of difficult-to-manage biliary stones

Seven abstracts and data analyses to be presented May 19 – 22 in San Diego.

Two-year clinical data demonstrate low adverse event rates, including no myocardial infarction or stent thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent

New self-expanding Nitinol stent offers balance of flexibility and radial strength for enhanced performance in iliac stenting procedures.

Follow-up data from EVOLVE Trial presented at EuroPCR.

Results of REPRISE I study suggest device minimizes aortic regurgitation

Innovative stent designed to treat peripheral vascular lesions for stenoses in arteries above the knee.

Collaboration expected to improve access to imaging data used to treat patients.

Results presented at Heart Rhythm Society from ASA Plavix study evaluating Boston Scientific Left Atrial Appendage Closure Device.